Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions [Benzinga]
Monday, November 4, 2024 1 min read
Key Takeaway: Enveric Biosciences Inc has expanded its intellectual property with the acquisition of five new U.S. patents for its EVM301 portfolio. This increase brings the total number of issued patents to nine, reinforcing the company's commitment to developing neuropsychiatric treatments. The patents pertain to compounds that target mental health conditions through neuroplasticity.
Price reaction · baseline $88.506 (2024-11-01 close) · hit pre-market · 1 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
-5.6%
day 1
-4.4%
day 3
-3.4%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric has secured five new U.S. patents.
Total patents now number nine, strengthening their portfolio.
Focus on neuroplasticity compounds for mental health is promising.
Full Press Release Details
Enveric Biosciences Inc, a biotechnology company focused on neuropsychiatric treatment development, has secured five new U.S. patents for its EVM301 portfolio. This latest additions bring Enveric’s total to nine issued U.S. patents, enhancing the intellectual property surrounding its library of neuroplasticity-focused compounds aimed at mental health conditions.
Full Article >>
Frequently Asked Questions
What is the focus of Enveric Biosciences?
Enveric Biosciences focuses on developing treatments for neuropsychiatric conditions.
How many U.S. patents does Enveric now hold?
Enveric Biosciences now holds a total of nine issued U.S. patents.
What is the significance of the new patents?
The new patents enhance Enveric's intellectual property for neuroplasticity-focused compounds.
What is the EVM301 portfolio?
The EVM301 portfolio includes compounds aimed at treating mental health conditions.